Succipro was founded in 2022 as a spin-off from the Pere Virgili Health Research Institute (IISPV) and Rovira i Virgili University (URV), driven by the desire to transform scientific discoveries into real therapeutic solutions. With a strong foundation in succinate research as a therapeutic target, we have evolved into a leader in the development of succinate-modulating drugs, aimed at treating metabolic and inflammatory diseases.
Our journey has been marked by collaboration with scientific institutions, pharmaceutical companies, and investors, enabling us to advance toward safe and effective solutions that transform patients’ lives.
We have a multidisciplinary team composed of researchers, scientists, doctors, and highly qualified professionals with extensive experience in drug development and the treatment of chronic diseases.
We work closely with internationally recognized specialists and collaborate with leading academic institutions to ensure that our projects remain at the forefront of scientific and pharmaceutical innovation.